Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients

被引:0
|
作者
Hye-Yoon Song
Kyung-Bok Son
Ju-Young Shin
SeungJin Bae
机构
[1] Ewha Womans University,College of Pharmacy
[2] Sungkyunkwan University,School of Pharmacy
关键词
Anticoagulant; NOAC; Nonvalvular atrial fibrillation; Prescribing; South korea; Vitamin-K antagonist;
D O I
暂无
中图分类号
学科分类号
摘要
Background Although the majority of clinical guidelines indicate the use of NOAC (nonvitamin K antagonist oral anticoagulant) over vitamin K antagonist in nonvalvular atrial fibrillation patients, there is no information on real-world prescription factors that lead to a specific type of oral anticoagulant selection. Objective To evaluate the prescription factors for choosing a specific oral anticoagulant for nonvalvular atrial fibrillation patients in Korea. Setting Nationwide sampled database in South Korea. Methods In this study, we defined nonvalvular atrial fibrillation patients as having one or more hospitalizations or two or more out-patient visits with a stroke risk score (CHA2DS2-VASc scores) ≥ 2 eligible for oral anticoagulant therapy from Jan 1st, 2016 to Dec 31st, 2016. Baseline characteristics were analyzed, including sex, age, comorbidities, CHA2DS2-VASc, bleeding risk score (mHAS-BLED), prescribing specialty, insurance type, medical institution type and location. Univariate and multivariate logistic regression analyses were conducted for being prescribed NOAC compared with vitamin K antagonist. Main outcome measure Adjusted odds ratio of the NOAC group and vitamin K antagonist group. Results Of 9,226 patients eligible for oral anticoagulant therapy, 4999 patients (54.2%) received oral anticoagulant therapy, and 4517 patients took NOAC or vitamin K antagonist only during the study period. Prior stroke, transient ischemic attack, thromboembolism, thyroid disease, dyslipidemia, cancer, mHAS-BLED ≥ 5, in-patient care, and specialty in internal medicine and neurology were positive predictors of NOAC use over vitamin K antagonist, whereas young age (≤64), renal dysfunction, and secondary care institution were negative predictors of NOAC use over vitamin K antagonist. Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.
引用
收藏
页码:1434 / 1441
页数:7
相关论文
共 50 条
  • [1] Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients
    Song, Hye-Yoon
    Son, Kyung-Bok
    Shin, Ju-Young
    Bae, SeungJin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (06) : 1434 - 1441
  • [2] New oral anticoagulants for patients with nonvalvular atrial fibrillation
    Holden, Amber
    Azimi, Nassir
    Forest, Christopher P.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2015, 28 (11): : 28 - 34
  • [3] Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
    Ferro, D.
    Loffredo, L.
    Polimeni, L.
    Violi, F.
    INTERNAL AND EMERGENCY MEDICINE, 2007, 2 (01) : 24 - 28
  • [4] Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
    D. Ferro
    L. Loffredo
    L. Polimeni
    F. Violi
    Internal and Emergency Medicine, 2007, 2 : 24 - 28
  • [5] Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
    Davis, Margot K.
    Lim, Howard
    Lee, Agnes Y. Y.
    JACC: CARDIOONCOLOGY, 2021, 3 (03): : 425 - 427
  • [6] New Oral Anticoagulants in Nonvalvular Atrial Fibrillation
    Urooj, Fatima
    Kulkarni, Abhishek
    Stapleton, Dwight
    Kaluski, Edo
    CLINICAL CARDIOLOGY, 2016, 39 (02) : 739 - 746
  • [7] New oral anticoagulants in nonvalvular atrial fibrillation
    Lega, Jean-Christophe
    Bertoletti, Laurent
    Durupt, Stephane
    Epinat, Magali
    Mismetti, Patrick
    Da Costa, Antoine
    Laporte, Silvy
    PRESSE MEDICALE, 2013, 42 (09): : 1225 - 1231
  • [8] Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
    Gabilondo, Miren
    Loza, Jesus
    Pereda, Angel
    Caballero, Ohiane
    Zamora, Nerea
    Gorostiza, Ania
    Mar, Javier
    HEMATOLOGY, 2021, 26 (01) : 277 - 283
  • [9] Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation
    Marin, Francisco
    Anguita-Sanchez, Manuel
    Sanmartin, Marcelo
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (01) : 67 - 77
  • [10] DIRECT ORAL ANTICOAGULANTS AND THE INCIDENCE OF DEMENTIA IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Rahman, A.
    Johnson, K.
    Michaud, J.
    Moodie, E.
    Brophy, J.
    Boivin, J. -F.
    Renoux, C.
    INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (03) : 115 - 116